EUVIMEDEUVIMED entdecken
Open Access

Inhibition of Parkinson’s disease–related LRRK2 by type I and type II kinase inhibitors: Activity and structures

Marta Sanz Murillo iD, Amalia Villagran Suarez iD, Verena Dederer iD, Deep Chatterjee, Jaime Alegrio Louro iD, Stefan Knapp iD, Sebastian Mathea iD, Andres E Leschziner iD

Science Advances · 2023-12 · 9 (48)

DOI: 10.1126/sciadv.adk6191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2023-12. Verfasst von Marta Sanz Murillo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular and Molecular Medicine, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in leucine-rich repeat kinase 2 (LRRK2) are a common cause of familial Parkinson’s disease (PD) and a risk factor for the sporadic form. Increased kinase activity was shown in patients with both familial and sporadic PD, making LRRK2 kinase inhibitors a major focus of drug development efforts. Although much progress has been made in understanding the structural biology of LRRK2, there are no available structures of LRRK2 inhibitor complexes. To this end, we solved cryo–electron microscopy structures of LRRK2, wild-type and PD-linked mutants, bound to the LRRK2-specific type I inhibitor MLi-2 and the broad-spectrum type II inhibitor GZD-824. Our structures revealed an active-like LRRK2 kinase in the type I inhibitor complex, and an inactive DYG-out in the type II inhibitor complex. Our structural analysis also showed how inhibitor-induced conformational changes in LRRK2 are affected by its autoinhibitory N-terminal repeats. The structures provide a template for the rational development of LRRK2 kinase inhibitors covering both canonical inhibitor binding modes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Cryoelectron MicroscopyPhosphorylationMutation

Substanzen

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, human

Autor:innen und Institutionen

  • Department of Cellular and Molecular Medicine, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
  • Aligning Science Across Parkinson's (ASAP) Collaborative Researcg Network, Chevy Chase, MD 20815, USA..
  • Institute of Pharmaceutical Chemistry, Goethe-Universität, Frankfurt 60438, Germany.
  • Structural Genomics Consortium (SGC), Buchmann Institute for Life Sciences, Goethe-Universität, Frankfurt 60438, Germany.
  • Department of Molecular Biology, School of Biological Sciences, University of California San Diego, La Jolla, CA 92093, USA.

ORCID-Profile: Marta Sanz Murillo, Amalia Villagran Suarez, Verena Dederer, Jaime Alegrio Louro, Stefan Knapp, Sebastian Mathea, Andres E Leschziner

Förderung

  • NIGMS NIH HHS

Zitieren

APA

Sanz Murillo, M., Villagran Suarez, A., Dederer, V., Chatterjee, D., Alegrio Louro, J., Knapp, S., Mathea, S., & Leschziner, A. E. (2023). Inhibition of Parkinson’s disease–related LRRK2 by type I and type II kinase inhibitors: Activity and structures. Science Advances, 9(48). https://doi.org/10.1126/sciadv.adk6191

Vancouver

Sanz Murillo M, Villagran Suarez A, Dederer V, Chatterjee D, Alegrio Louro J, Knapp S, et al. Inhibition of Parkinson’s disease–related LRRK2 by type I and type II kinase inhibitors: Activity and structures. Science Advances. 2023;9(48). doi:10.1126/sciadv.adk6191

BibTeX
@article{SanzMurillo2023,
  author = {Sanz Murillo, Marta and Villagran Suarez, Amalia and Dederer, Verena and Chatterjee, Deep and Alegrio Louro, Jaime and Knapp, Stefan and Mathea, Sebastian and Leschziner, Andres E},
  title = {Inhibition of Parkinson’s disease–related LRRK2 by type I and type II kinase inhibitors: Activity and structures},
  journal = {Science Advances},
  year = {2023},
  volume = {9},
  number = {48},
  doi = {10.1126/sciadv.adk6191}
}
Kostenlos starten →